Immunogens for HIV vaccination

Patent metadata

Field	Value
Publication number	US-9988425-B2
Application number	US-201314374334-A
Country	US
Kind code	B2
Filing date	Jan 28, 2013
Priority date	Jan 27, 2012
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including the immunogens.

First claim

The invention claimed is:

1. A nucleic acid molecule encoding an immunogenic polypeptide, wherein the immunogenic polypeptide comprises:
i) a sequence having at least 90% identity to the sequence of SEQ ID NO:1,
ii) a sequence having at least 90% identity to the sequence of SEQ ID NO:2,
iii) a sequence having at least 90% identity to the sequence of SEQ ID NO:3,
iv) a sequence having at least 90% identity to the sequence of SEQ ID NO:4,
v) a sequence having at least 90% identity to the sequence of SEQ ID NO:5,
vi) a sequence having at least 90% identity to the sequence of SEQ ID NO:6,
vii) a sequence having at least 90% identity to the sequence of SEQ ID NO:7,
viii) a sequence having at least 90% identity to the sequence of SEQ ID NO:8,
ix) a sequence having at least 90% identity to the sequence of SEQ ID NO:9,
x) a sequence having at least 90% identity to the sequence of SEQ ID NO:10,
xi) a sequence having at least 90% identity to the sequence of SEQ ID NO:11,
xii) a sequence having at least 90% identity to the sequence of SEQ ID NO:12,
xiii) a sequence having at least 90% identity to the sequence of SEQ ID NO:13,
xiv) a sequence having at least 90% identity to the sequence of SEQ ID NO:14,
xv) a sequence having at least 90% identity to the sequence of SEQ ID NO:15, and
xvi) a sequence having at least 90% identity to the sequence of SEQ ID NO:16; and
wherein at least two of i)-xvi) are joined by a single, dual, or triple alanine amino acid linker, wherein the linker results in the formation of an AAA sequence in the junction region between adjoining sequences, and
wherein the sequence of each of i)-xvi) is 11-85 amino acids in length.

2. The nucleic acid molecule of claim 1 , wherein the immunogenic polypeptide comprises:
i) a sequence having at least 95% identity to the sequence of SEQ ID NO:1,
ii) a sequence having at least 95% identity to the sequence of SEQ ID NO:2,
iii) a sequence having at least 95% identity to the sequence of SEQ ID NO:3,
iv) a sequence having at least 95% identity to the sequence of SEQ ID NO:4,
v) a sequence having at least 95% identity to the sequence of SEQ ID NO:5,
vi) a sequence having at least 95% identity to the sequence of SEQ ID NO:6,
vii) a sequence having at least 95% identity to the sequence of SEQ ID NO:7,
viii) a sequence having at least 95% identity to the sequence of SEQ ID NO:8,
ix) a sequence having at least 95% identity to the sequence of SEQ ID NO:9,
x) a sequence having at least 95% identity to the sequence of SEQ ID NO:10,
xi) a sequence having at least 95% identity to the sequence of SEQ ID NO:11,
xii) a sequence having at least 95% identity to the sequence of SEQ ID NO:12,
xiii) a sequence having at least 95% identity to the sequence of SEQ ID NO:13,
xiv) a sequence having at least 95% identity to the sequence of SEQ ID NO:14,
xv) a sequence having at least 95% identity to the sequence of SEQ ID NO:15, and
xvi) a sequence having at least 95% identity to the sequence of SEQ ID NO:16.

3. The nucleic acid of claim 1 , wherein the immunogenic polypeptide comprises the sequences of SEQ ID NOs:1-16, and wherein at least two of SEQ ID NOs:1-16 are joined by the single, dual, or triple alanine amino acid linker, and wherein the linker results in the formation of an AAA sequence in the junction region between adjoining sequences.

4. The nucleic acid molecule of claim 3 , wherein the immunogenic polypeptide has the sequence of SEQ ID NO:99.

5. The nucleic acid molecule of claim 4 , wherein the nucleic acid molecule has the sequence of SEQ ID NO:100.

6. A nucleic acid molecule encoding an immunogenic polypeptide, wherein the immunogenic polypeptide comprises:
i) a sequence having at least 90% identity to the sequence of SEQ ID NO:1,
ii) a sequence having at least 90% identity to the sequence of SEQ ID NO:2,
iii) a sequence having at least 90% identity to the sequence of SEQ ID NO:3,
iv) a sequence having at least 90% identity to the sequence of SEQ ID NO:4,
v) a sequence having at least 90% identity to the sequence of SEQ ID NO:5,
vi) a sequence having at least 90% identity to the sequence of SEQ ID NO:6,
vii) a sequence having at least 90% identity to the sequence of SEQ ID NO:7,
viii) a sequence having at least 90% identity to the sequence of SEQ ID NO:8,
ix) a sequence having at least 90% identity to the sequence of SEQ ID NO:9,
x) a sequence having at least 90% identity to the sequence of SEQ ID NO:10,
xi) a sequence having at least 90% identity to the sequence of SEQ ID NO:11,
xii) a sequence having at least 90% identity to the sequence of SEQ ID NO:12,
xiii) a sequence having at least 90% identity to the sequence of SEQ ID NO:13,
xiv) a sequence having at least 90% identity to the sequence of SEQ ID NO:14,
xv) a sequence having at least 90% identity to the sequence of SEQ ID NO:15, and
xvi) a sequence having at least 90% identity to the sequence of SEQ ID NO:16;
wherein at least two of i)-xvi) are joined by an amino acid linker, wherein the sequence of each of i)-xvi) is 11-85 amino acids in length, and wherein the nucleic acid molecule is codon optimized for expression in human cells.

7. A virus comprising the nucleic acid molecule of claim 1 .

8. A Modified Vaccinia Ankara virus comprising a nucleic acid molecule encoding an immunogenic polypeptide, wherein the immunogenic polypeptide comprises:
i) a sequence having at least 90% identity to the sequence of SEQ ID NO:1,
ii) a sequence having at least 90% identity to the sequence of SEQ ID NO:2,
iii) a sequence having at least 90% identity to the sequence of SEQ ID NO:3,
iv) a sequence having at least 90% identity to the sequence of SEQ ID NO:4,
v) a sequence having at least 90% identity to the sequence of SEQ ID NO:5,
vi) a sequence having at least 90% identity to the sequence of SEQ ID NO:6,
vii) a sequence having at least 90% identity to the sequence of SEQ ID NO:7,
viii) a sequence having at least 90% identity to the sequence of SEQ ID NO:8,
ix) a sequence having at least 90% identity to the sequence of SEQ ID NO:9,
x) a sequence having at least 90% identity to the sequence of SEQ ID NO:10,
xi) a sequence having at least 90% identity to the sequence of SEQ ID NO:11,
xii) a sequence having at least 90% identity to the sequence of SEQ ID NO:12,
xiii) a sequence having at least 90% identity to the sequence of SEQ ID NO:13,
xiv) a sequence having at least 90% identity to the sequence of SEQ ID NO:14,
xv) a sequence having at least 90% identity to the sequence of SEQ ID NO:15, and
xvi) a sequence having at least 90% identity to the sequence of SEQ ID NO:16;
wherein at least two of i)-xvi) are joined by an amino acid linker, and wherein the sequence of each of i)-xvi) is 11-85 amino acids in length.

9. A cell comprising the nucleic acid molecule of claim 1 .

10. A nucleic acid molecule encoding an immunogenic polypeptide wherein the immunogenic polypeptide comprises:
i) the sequence of SEQ ID NO:1 or a sequence derived therefrom by one or more conservative amino acid substitutions,
ii) the sequence of SEQ ID NO:2 or a sequence derived therefrom by one or more conservative amino acid substitutions,
iii) the sequence of SEQ ID NO:3 or a sequence derived therefrom by one or more conservative amino acid substitutions,
iv) the sequence of SEQ ID NO:4 or a sequence derived therefrom by one or more conservative amino acid substitutions,
v) the sequence of SEQ ID NO:5 or a sequence derived therefrom by one or more conservative amino acid substitutions,
vi) the sequence of SEQ ID NO:6 or a sequence derived therefrom by one or more conservative amino acid substitutions,
vii) the sequence of SEQ ID NO:7 or a sequence der

Assignees

• Esteve Labor Dr
• Fundacio Privada Inst De Recerca De La Sida—Caixa
• Esteve Labor Dr

Inventors

• Brander Christian
• Mothe Pujadas Beatriz
• Llano Anuska

Classifications

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K14/005 Primary

  from viruses · CPC title

• A61P31/18

  for HIV · CPC title

• A61K2039/5256

  expressing foreign proteins · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title